Document is current

Article History

Received: 7 February 2024

Accepted: 10 September 2024

First Online: 17 September 2024

Declarations

:

: This is a retrospective study performed on data from the IQVIA database, a global healthcare leader that acts in accordance with Nuremberg Code, Belmont Report, Declaration of Helsinki, and the consensus of the global medical-ethics community. IQVIA uses an objective, evidence-driven, transparent approach to help protect the safety and anonymity of data, overseen by the Office of the Chief Medical and Scientific Officer in the IQVIA ethics committee.

: IQVIA does not use patient-identifiable personal information in data collection, any and all patient collected data was only utilized after appropriate informed consent was obtained, a policy enforced by the IQVIA Global Chief Privacy Officer.

: This manuscript does not contain any individual person(s) living or dead identifiable data in any form including details, images or videos. IQVIA has strict internal and external controls to respect the privacy of patients by avoiding the use of any patient-identifiable information in any data.

: Lee Schwartzberg has received funding as a Consultant from AstraZeneca, Daiichi Sankyo, Genentech, Novartis, Pfizer, Seagen, Spectrum, Napo Pharmaceuticals, GlaxoSmithKline, Foundation Medicine and as a speaker from AstraZeneca, Seagen, Merck, and Pfizer. Pablo Okhuysen has received funding as a consultant and investigator from NAPO Pharmaceuticals, Summit Pharmaceuticals (investigator), Deinove Pharmaceuticals (investigator), Merck Sharp and Dohme (investigator), Kleberg Foundation (investigator), SNIPR Biome (consultant), Ferring Pharmaceuticals (consultant). The remaining authors declare that the research was conducted without any conflicts of interest.